SynRG Becomes First Russian Member of European Forum for Good Clinical Practice

Wednesday, December 16, 2009 06:44 AM

Russia-based contract research organization (CRO) SynRG recently became the first Russian member of the European Forum for Good Clinical Practice (EFGCP), an organization created in 1993 to help develop and evaluate European health research. One of the EFGCP’s main purposes is to promote Good Clinical Practice (GCP) throughout Europe.

“We have a mutual interest in facilitating the conduct of clinical research projects in Russia to the highest standards of GCP, by providing appropriate information and training of investigators and ethics committees in these standards,” said Frank Wells, EFGCP’s Ethics Officer.

Through SynRG’s participation in the organization, EFGCP hopes to establish a dialogue with Russian non-profit and government institutions involved in clinical trials in Russia, as well as launch EFGCP training programs for Russia-based CRAs, investigators and members of the local ethics committees. SynRG hopes its participation in the organization will improve Russia’s clinical trial market and help the company attract foreign study sponsors.

 

Share:          
CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs